Literature DB >> 6105079

Measurement of hepatic drug-metabolizing enxyme activity in man. Comparison of three different assays.

E A Sotaniemi, R O Pelkonen, M Puukka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6105079     DOI： 10.1007/bf00625800

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  34 in total

1.  CHANGES IN ENZYME ACTIVITY, RELATED TO D-GLUCARIC ACID SYNTHESIS, WITH AGE, PREGNANCY AND MALIGNANCY.

Authors:  C A MARSH; A J CARR
Journal:  Clin Sci       Date:  1965-04       Impact factor: 6.124

2.  Urinary D-glucaric acid excretion and plasma antipyrine kinetics during enzyme induction.

Authors:  M Davis; C J Simmons; B Dordoni; R Williams
Journal:  Br J Clin Pharmacol       Date:  1974-06       Impact factor: 4.335

3.  Effects of medroxyprogesterone on the liver function and drug metabolism of patients with primary biliary cirrhosis and chronic active hepatitis.

Authors:  E A Sotaniemi; T Hynnynen; J Ahlqvist; J T Ahokas; U Puoskari; I Pelkonen
Journal:  J Med       Date:  1978

4.  Urinary D-glucaric acid excretion and acetanilide pharmacokinetics before and during diphenylhydantoin administration.

Authors:  J L Cunningham; D A Evans
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

5.  Editorial: Drug metabolism in disease.

Authors: 
Journal:  Lancet       Date:  1974-04-27       Impact factor: 79.321

6.  Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man.

Authors:  J Hunter; J D Maxwell; M Carrella; D A Stewart; R Williams
Journal:  Lancet       Date:  1971-03-20       Impact factor: 79.321

7.  Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol.

Authors:  S E Smith; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

8.  Glucaric acid as an indicator of use of enzyme-inducing drugs.

Authors:  E A Sotaniemi; F Medzihradsky; G Eliasson
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

9.  Comparative metabolism of benzo[a]pyrene and drugs in human liver.

Authors:  J Kapitulnik; P J Popper; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1977-02       Impact factor: 6.875

10.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059
View more
  6 in total

1.  Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.

Authors:  P V Luoma; E A Sotaniemi; R O Pelkonen; A Arranto; C Ehnholm
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

2.  Serum selenium, glutathione peroxidase, lipids, and human liver microsomal enzyme activity : A double-blind controlled trial of selenium supplementation.

Authors:  P V Luoma; H Korpela; E A Sotaniemi; J Kumpulainen
Journal:  Biol Trace Elem Res       Date:  1985-09       Impact factor: 3.738

Review 3.  Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.

Authors:  M Døssing
Journal:  Int Arch Occup Environ Health       Date:  1984       Impact factor: 3.015

4.  Saliva and plasma clearance of antipyrine as reflectors of liver function.

Authors:  P V Luoma; E A Sotaniemi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

5.  Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations.

Authors:  Simona Rossi; David N Assis; Monica Awsare; Mark Brunner; Kevin Skole; Jitha Rai; Jocelyn Andrel; Steven K Herrine; Rajender K Reddy; Victor J Navarro
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 6.  Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature.

Authors:  Thomas M Caparrotta; Daniel J Antoine; James W Dear
Journal:  Eur J Clin Pharmacol       Date:  2017-10-24       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.